Belgium-based ThromboGenics has received approval from the Australia’s Therapeutic Goods Administration (TGA), for its Jetrea (ocriplasmin) to treat adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400µ.

Jetrea is a selective proteolytic enzyme, which cleaves fibronectin, laminin and collagen, the components of the vitreoretinal interface that play a crucial role in vitreomacular adhesion.

"Jetrea is a truncated form of human plasmin, indicated for treatment of symptomatic vitreomacular adhesion in the US."

ThromboGenics’ partner Alcon, a division of Novartis, will introduce the drug in Australia, which received exclusive rights to commercialise Jetrea outside the US in March 2012.

Jetrea is a truncated form of human plasmin, which is indicated for treatment of symptomatic vitreomacular adhesion (VMA) in the US. It was approved by the US FDA in 2013.

It was assessed in two multi-centre randomised, double-masked Phase III trials conducted in the US and Europe, which involved 652 patients with vitreomacular adhesion. Both the trials reached primary endpoint of resolution of VMA at day 28.

In the Phase III programme, around 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared against 10.1% of patients receiving placebo, said the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In March this year, Jetrea received approval from the Swiss Agency for Therapeutic Products, Swissmedic, to treat adults with vitreomacular traction (VMT), including when associated with a macular hole of diameter less than or equal to 400µ.

Alcon launched the drug in the UK in April 2013, and is also available in the Germany, Denmark, Finland, Norway, Sweden, Ireland, the Netherlands and Canada.